3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
cyclopia sequence
7
Neoplasms
6
Multiple Myeloma
6
Fatigue
6
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Dyspnea
4
Carcinoma, Non-Small-Cell Lung
4
Anxiety Disorders
4
Uterine Cervical Neoplasms
3
Tobacco Use Cessation
3
Prostatic Neoplasms
3
Primary Myelofibrosis
3
Leukemia
3
Head and Neck Neoplasms
3
Depression
3
Carcinoma, Renal Cell
3
Vomiting
2
Smoking Cessation
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycythemia Vera
2
Parasomnias
2
Pancreatic Neoplasms
2
Pain
2
Osteosarcoma
2
Kidney Neoplasms
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Interventions
BNT162 Vaccine
2
2019-nCoV Vaccine mRNA-1273
2
tocilizumab
1
sotrovimab
1
proxalutamide
1
bemcentinib
1
Therapeutics
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Sodium Chloride
1
Radiotherapy
1
Patient Reported Outcome Measures
1
Janus Kinase Inhibitors
1
Influenza Vaccines
1
Hydroxychloroquine
1
HuMax-IL8
1
Gelsolin
1
Diagnostic Tests, Routine
1
Decision Support Techniques
1
COVID-19 Vaccines
1
Blood Specimen Collection
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
COVID-19
×
Surveys and Questionnaires
×
Clear all
NCT04872738
2026-01-06
LymphVAX
Massachusetts General Hospital
Completed
714 enrolled
7 charts